DRUG · Mapped RxNorm record
Donanemab
Normalized identity: donanemabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Alzheimer Diseaseverified · MONDO: Alzheimer disease
Dementiaverified · MONDO: dementia
Plaque, Amyloidunresolved
Interventions
DonanemabDRUG · verified · RxNorm: donanemab
PlaceboDRUG
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
MiamiFlorida, United States2TampaFlorida, United States2IndianapolisIndiana, United States2OrlandoFlorida, United States2HoustonTexas, United States1ChicagoIllinois, United States1San DiegoCalifornia, United States1PhoenixArizona, United States1JacksonvilleFlorida, United States1AustinTexas, United States1Las VegasNevada, United States1SacramentoCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07602582 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.